Unity Biotechnology Unveils Combined Information From Research For Diabetes-Associated Blindness, Inventory Falls – Unity Biotechnology (NASDAQ:UBX)

Unity Biotechnology, Inc. UBX inventory plummeted on Monday after the corporate launched outcomes from its newest examine.

The Part 2b ASPIRE medical trial of intravitreal UBX1325 involed sufferers with diabetic macular edema (DME) who had poor imaginative and prescient regardless of prior anti-VEGF therapy.

The examine outcomes embody information from all sufferers by means of 24 weeks and most sufferers by means of 36 weeks.

UBX1325 therapy led to visible acuity features of over 5 letters from baseline at weeks 24 and 36 and achieved non-inferiority to Regeneraon Prescribed drugs Inc’s REGN Eylea (aflibercept) at 9 out of 10-time factors by means of 36 weeks.

Additionally Learn: GE Aerospace Opens XEOS Facility To Energy Up LEAP Engine Overhauls: Particulars

• UBX1325-treated sufferers had a imply change in BCVA of +5.2 ETDRS letters from baseline to 24 weeks, representing a distinction of +0.4 ETDRS letters in comparison with the aflibercept arm.
• UBX1325-treated sufferers had a imply change in BCVA of +5.5 ETDRS letters from baseline to 36 weeks, representing a distinction of +0.2 ETDRS letters in comparison with the aflibercept arm.
• UBX1325 was non-inferior to aflibercept in any respect time factors by means of 36 weeks, aside from the common of weeks 20 and 24
• Sufferers on UBX1325 had a rise in Central Subfield Thickness (CST) at weeks 16 and 20, which resulted in supplemental anti-VEGF therapies in sufferers with important CST achieve.
• UBX1325 usually outperformed aflibercept in sufferers who had average illness severity (baseline CST < 400 microns, representing ~60% of examine sufferers) (pre-specified evaluation)
• Sufferers who switched from aflibercept as their anti-VEGF therapy earlier than examine enrollment to UBX1325 had probably the most constant and sturdy imaginative and prescient features (pre-specified evaluation)

UBX1325 continues to reveal a positive security and tolerability profile.

Unity anticipates the whole 36-week information outcomes of the remaining sufferers within the second quarter of 2025.

As of December 31, 2024, money, money equivalents, and marketable securities totaled $23.2 million, adequate to fund operations into the fourth quarter of 2025.

Value Motion: UBX inventory is down 34.8% at $1.19 on the final examine Monday.

Learn Subsequent: